Home » Stocks » CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC)

Stock Price: $5.09 USD -0.01 (-0.20%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $5.14 +0.05 (0.98%) Jul 29, 4:30 PM
Market Cap 48.29M
Revenue (ttm) 150,000
Net Income (ttm) -14.68M
Shares Out 7.10M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $5.09
Previous Close $5.10
Change ($) -0.01
Change (%) -0.20%
Day's Open 5.11
Day's Range 5.05 - 5.20
Day's Volume 63,117
52-Week Range 3.12 - 11.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study- -Next-Generation CDK2/9 Inhibitor Fadraciclib to ...

Other stocks mentioned: CYCCP
2 weeks ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

Other stocks mentioned: CYCCP
3 weeks ago - GlobeNewsWire

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -  - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -  - Following Rece...

Other stocks mentioned: CYCCP
2 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...

Other stocks mentioned: CYCCP
2 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

Other stocks mentioned: CYCCP
4 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

Other stocks mentioned: CYCCP
4 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will ...

Other stocks mentioned: CYCCP
4 months ago - Benzinga

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

Other stocks mentioned: CYCCP
4 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

Other stocks mentioned: CYCCP
4 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

Other stocks mentioned: CYCCP
5 months ago - GlobeNewsWire

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fun...

Other stocks mentioned: CYCCP
6 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

Other stocks mentioned: CYCCP
6 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: CYCCP
8 months ago - Seeking Alpha

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medic...

Other stocks mentioned: CYCCP
8 months ago - GlobeNewsWire

A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved parti...

Other stocks mentioned: CYCCP
9 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...

Other stocks mentioned: CYCCP
9 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...

Other stocks mentioned: CYCCP
9 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative me...

Other stocks mentioned: CYCCP
10 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - - Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -

Other stocks mentioned: CYCCP
11 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

Other stocks mentioned: CYCCP
11 months ago - GlobeNewsWire

Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

1 year ago - Zacks Investment Research

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: CYCCP
1 year ago - Seeking Alpha

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET -

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative ...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) shares were crushed on Tuesday after the company announced the pricing of a secondary offering.

Other stocks mentioned: CYCCP
1 year ago - 24/7 Wall Street

BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative ...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications arising fr...

1 year ago - Benzinga

-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- -Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Infla...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative ...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

1 year ago - Zacks Investment Research

CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

Other stocks mentioned: CYCCP
1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanc... [Read more...]

Industry
Biotechnology
Founded
1992
CEO
Spiro Rombotis
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
CYCC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CYCC stock is "Strong Buy." The 12-month stock price forecast is 20.25, which is an increase of 297.84% from the latest price.

Price Target
$20.25
(297.84% upside)
Analyst Consensus: Strong Buy